Officials in Europe and South Korea are vying for Gilead Sciences' potential COVID-19 treatment remdesivir, even though the company has not yet been awarded regulatory approval in either market, and is still ramping up production of the experimental antiviral, as reported in the Financial Post.
The European Medicines Agency (EMA) noted it has not yet received an application from Gilead, but said the timeline for its Committee for Medicinal Products for Human Use to review the drug would be "reduced to the absolute minimum."
The EMA recently told the European Parliament it may authorise remdesivir as a COVID-19 treatment, fast-tracking the drug to market amid tight global competition for resources.
On Friday, South Korean health authorities said they would request imports of remdesivir to treat COVID-19, as new outbreaks of the disease flare after social distancing restrictions were eased.
Gilead has said it expects to have more than a million remdesivir treatment courses manufactured by December, "with plans to be able to produce several million treatment courses in 2021."
To read more NewsPoints articles, click here.